Signaling pathways in apoptosis as potential targets for cancer therapy
- 1 August 2001
- journal article
- review article
- Published by Elsevier in Trends in Cell Biology
- Vol. 11 (8) , 343-348
- https://doi.org/10.1016/s0962-8924(01)02063-3
Abstract
No abstract availableKeywords
This publication has 60 references indexed in Scilit:
- Phase I Trial of 72-Hour Continuous Infusion UCN-01 in Patients With Refractory NeoplasmsJournal of Clinical Oncology, 2001
- Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid LeukemiaNew England Journal of Medicine, 2001
- Phase II Study of the Cyclin-Dependent Kinase Inhibitor Flavopiridol Administered to Patients With Advanced Gastric CarcinomaJournal of Clinical Oncology, 2001
- Nuclear and mitochondrial apoptotic pathways of p53Published by Wiley ,2001
- Inactivation of the apoptosis effector Apaf-1 in malignant melanomaNature, 2001
- Small molecule modulators of cyclin-dependent kinases for cancer therapyOncogene, 2000
- p53Cell, 2000
- Primary cells suppress oncogene-dependent apoptosisNature Cell Biology, 2000
- CGP57148B (STI-571) induces differentiation and apoptosis and sensitizes Bcr-Abl–positive human leukemia cells to apoptosis due to antileukemic drugsBlood, 2000
- c-Myc-induced sensitization to apoptosis is mediated through cytochrome c releaseGenes & Development, 1999